TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：2
|
作者：
Bloom, Stuart [1 ]
Lichtenstein, Gary R. [2 ]
Loftus, Edward V. [3 ]
Lawendy, Nervin [4 ]
Friedman, Gary S. [4 ]
Zhang, Haiying [4 ]
Wang, Wenjin [4 ]
Thorpe, Andrew J. [4 ]
Nduaka, Chudy I. [4 ]
Su, Chinyu [4 ]
机构：
[1] Ucl Hosp Bhs Fdn Trust, London, England
[2] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[3] Mayo Clin, Rochester, MN USA
[4] Pfizer Inc, Collegeville, PA USA
来源：
GUT | 2018年 / 67卷
关键词：
D O I：
10.1136/gutjnl-2018-BSGAbstracts.123
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PTU-001
引用
收藏
页码：A62 / A63
页数：2
相关论文
共 50 条
  • [1] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
  • [2] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Chan, Gary
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328
  • [3] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Soonasra, Arif
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
  • [4] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Wei, Shu Chen
    Damiao, Aderson O.
    Judd, Donna
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
  • [5] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [6] Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study
    Colombel, Jean-Frederic
    Reinisch, Walter
    Osterman, Mark T.
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Zhang, Haiying
    Lawendy, Nervin
    Friedman, Gary S.
    Su, Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S389 - S390
  • [7] Maintenance of Remission with Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis from an Open-Label, Long-Term Extension Study
    Jean-Frederic, Colombel
    Walter, Reinisch
    Mark, Osterman T.
    Andrew, Thorpe J.
    Chudy, Nduaka, I
    Zhang Haiying
    Nervin, Lawendy
    Gary, Friedman S.
    Su Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S4 - S4
  • [8] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
    Sandborn, William J.
    Lawendy, Nervin
    Danese, Silvio
    Su, Chinyu
    Loftus, Edward V., Jr.
    Hart, Ailsa
    Dotan, Iris
    Damiao, Aderson O. M. C.
    Judd, Donna T.
    Guo, Xiang
    Modesto, Irene
    Wang, Wenjin
    Panes, Julian
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478
  • [9] Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S351 - S352
  • [10] Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S351 - S351
12345